Michael chats with Dr. William Audeh, Chief Medical Officer at Agendia. Together, they discuss recent advancements in genomic testing for early-stage breast cancer, how Agendia's MammaPrint® and BluePrint® genomic assays go beyond answering the question of "chemo or no chemo," how decisions based on genomic insights offer improved precision in guiding treatment decisions for patients and their physicians, the future of genomic testing, how the FLEX Study is helping answer clinical questions, and much more.

To learn more about Agendia, MammaPrint, and BluePrint, visit www.agendia.com.